A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Status:
Terminated
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder
cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based
neoadjuvant therapy. The target recruitment is 10 evaluable patients for this window of
opportunity study. Pre- and post-treatment tumor samples from transurethral resection of the
bladder tumor and RC will be used for study endpoints.